The above, and much more, is reported in Forbes, 8/05/2014; David Kroll, "Ebola Secret Serum: Small Biopharma, The Army, and Big Tobacco.
There are more comprehensive articles, but Kroll's column is clearly stated.
Tobacco enters into the story because Nicotiana bethamiana is a common plant molecular biology tool. The antibodies are produced in an Australian strain of the tobacco plant at a facility (Kentucky Bioprocessing) owned by Reynolds America Inc. (parent company of R. J. Reynolds Tobacco).

Funding for the research comes from several sources, including three U. S. government agencies; National Institute of Allergy and Infectious Disease, Department of Defense Advanced Research Projects, and Defense Threat Reduction Agency.

The serum prevented the death of six infected monkeys in research at the Maryland facility of the U. S, Army Medical Research Institute. Research here is led by microbiologist Gene Olinger.

Comprehensive reports have been published in Proceedings of the National Academy of Sciences and Sciences Translational Medicine.